Yeah, the problem with monoclonal antibodies, even the fully-human ones like adalimumab, golimumab, and secukinumab is that there is one little part of the antibody that is foreign to the patient, and that's the part that binds the TNF. About 1/3 patients will eventually form neutralizing antibodies.
The only one that has much less potential for this is etanercept. In the case of etanercept the entire protein is fully human and is found in every human living today. Antibody formation is much lower with etanercept.
